Medpace Holdings (MEDP) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $4.84
- Estimate
- $4.46
- Surprise
- +8.5%
- Revenue (period 2026-09-30)
- $716.0M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Medpace Holdings (MEDP) beat the $4.46 estimate with adjusted EPS of $4.84 — a clear 8.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MEDP Hold at 5.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +8.5% surprise compares with a +8.3% four-quarter average. Next scheduled report: 2027-02-08.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Customer: small biopharmaceutical companies (82.0%)
- Analyst target reached - limited upside remaining
- Near 52-week high (4.2% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $664.54
- Entry target
- $617.13
- Stop
- $587.59
At 36.9× trailing and 33.5× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.
MEDP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $18.59B
- P/E (fwd)
- 33.5
- P/E (ttm)
- 36.9
- 52-week range
- $373.00–$693.97
- Off 52-week high
- 4.2%
- RSI (14)
- 51
- Volume vs avg
- 0.49×
- Score today
- 5.5/10